WunTWhiteRH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol2009; 22: 9–23. 2009/03/17. DOI: 10.1016/j.beha.2008.12.001
2.
MegeDPanicot-DuboisLDuboisC. Mechanisms of cancer-associated thrombosis. HemaSphere2019; 3: 19–21.
3.
GordonSGFranksJJLewisB. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res1975; 6: 127–137. 1975/02/01. DOI: 10.1016/0049-3848(75)90018-3
4.
GordonSGMielickiWP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis1997; 8: 73–86. 1997/03/01.
5.
AlessioMGFalangaAConsonniR, et al.Cancer procoagulant in acute lymphoblastic leukemia. Eur J Haematol1990; 45: 78–81. 1990/08/01. DOI: 10.1111/j.1600-0609.1990.tb00421.x
6.
ZhangNLouWJiF, et al.Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. J Cancer Res Clin Oncol2016; 142: 1807–1816. 2016/02/26. DOI: 10.1007/s00432-016-2131-6
7.
BobekVKovaríkJ. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother2004; 58: 213–219. 2004/06/09. DOI: 10.1016/j.biopha.2003.11.007
8.
CarrierMAbou-NassarKMallickR, et al.Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med2019; 380: 711–719. 2018/12/05. DOI: 10.1056/NEJMoa1814468
9.
RaskobGEvan EsNVerhammeP, et al.Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med2018; 378: 615–624. 2017/12/13. DOI: 10.1056/NEJMoa1711948
10.
AsanumaKWakabayashiHHayashiT, et al.Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology2004; 67: 166–173. 2004/11/13. DOI: 10.1159/000081004
11.
OgawaMJingHKittsDD, et al.In vitro anti-cancer activities in caco-2 and HCT-116 cells of recombinant cystatin C prepared by a pichia expression system. J Med Food2003; 6: 317–322. 2004/02/24. DOI: 10.1089/109662003772519868
12.
BrüningAFrieseKBurgesA, et al.Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res2010; 12: R45. 2010/07/03. DOI: 10.1186/bcr2602
13.
GillsJJLopiccoloJTsurutaniJ, et al.Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res2007; 13: 5183–5194. 2007/09/06. DOI: 10.1158/1078-0432.ccr-07-0161
14.
ArigaTTsujKSekiT, et al.Antithrombotic and antineoplastic effects of phyto-organosulfur compounds. Biofactors2000; 13: 251–255. 2001/03/10. DOI: 10.1002/biof.5520130138
15.
ManjappaBGangarajuSGirishKS, et al.Momordica charantia seed extract exhibits strong anticoagulant effect by specifically interfering in intrinsic pathway of blood coagulation and dissolves fibrin clot. Blood Coagul Fibrinolysis2015; 26: 191–199. 2014/09/06. DOI: 10.1097/mbc.0000000000000191
16.
MinSKKwonOCLeeS, et al.An antithrombotic fucoidan, unlike heparin, does not prolong bleeding time in a murine arterial thrombosis model: a comparative study of undaria pinnatifida sporophylls and fucus vesiculosus. Phytother Res2012; 26: 752–757. 2011/11/16. DOI: 10.1002/ptr.3628
17.
WangHKhorTOShuL, et al.Plants vs. Cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem2012; 12: 1281–1305. 2012/05/16. DOI: 10.2174/187152012803833026
18.
CaineGJStonelakePSLipGY, et al.The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia2002; 4: 465–473. 2002/10/31. DOI: 10.1038/sj.neo.7900263
19.
FalangaAConsonniRMarchettiM, et al.Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood1998; 92: 143–151. 1998/06/25.
